{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Assessment of Management of Osteoporosis and Real World Use of Teriparatide by Orthopedicians across India (AMARTYA Survey)
Data Collection Form

Doctor’s Details

  1. Predominant type of practice *

    2. Type of practice

  2. Years of clinical practice *
    3. Years
  3. Place of practice *

  4. Which imaging modality do you use to diagnose osteoporosis in your facility? (Check all that apply) *

  5. How many patients of severe osteoporosis with T score ≤ - 2.5 do you see in a month at your facility? *

  6. What is the common age group of patients who present with severe osteoporosis with T score ≤ - 2.5 in your facility? *

  7. As per your clinical experience which bones get commonly affected due to osteoporosis? *

  8. What are the clinical indicators of osteoporosis in young patients in your facility? (Check all that apply) *

  9. How majority of patients visiting your facility are diagnosed as having osteoporosis? *

  10. The majority of osteoporosis patients referred to your facility by which specialties? (Mention percentages from each specialties) *
    11. General practitioners
    %
    Gynecologists
    %
    Endocrinologists
    %
    Consultant physicians
    %
    %

  11. What are the most common presenting complaints in your osteoporosis patients? (Check all that apply) *

  12. What are the most common findings on imaging in osteoporotic patients in your practice? *

  13. How many new patients with fractures do you see in a month? *

  14. What is the proportion of osteoporotic fractures among new fractures in every month? *

  15. What are the most common causes for osteoporosis observed in your clinical practice? *

  16. In which of the following patients with osteoporosis do you prescribe teriparatide *

  17. What pre-treatment assessment do you conduct before initiating treatment with teriparatide? (Check all that apply) *

  18. What are your treatment goals when you prescribe teriparatide for the treatment of osteoporosis? (Check all that apply) *

  19. In how many patients of osteoporotic fractures do you prescribe teriparatide pre-operatively? *

  20. In how many patients do you prescribe teriparatide after surgical fixation of osteoporotic fractures? *

  21. What is the treatment duration with teriparatide in the management of osteoporosis with fragility fracture? *

  22. How do you treat severe osteoporosis in patients with chronic renal failure? *

  23. How do you treat severe osteoporosis in patients of renal calculi? *

  24. Do you use teriparatide for the management of severe osteoporosis in patients with hepatic impairment? *

  25. Do you prescribe teriparatide and denosumab simultaneously to get optimum results in the management of severe osteoporosis? *

  26. According to you which regimen should be preferred in the management of severe osteoporosis *

  27. As per your clinical experience which statement is correct for teriparatide with respect to cancellous and cortical bones? *

  28. As per your clinical experience which statement is correct for teriparatide with respect to diaphyseal and metaphyseal bones? *

  29. Do you repeat the course of teriparatide therapy after discontinuation in same patient if he/she comes again with features of osteoporosis? *

  30. What are the barriers to use teriparatide in the management of osteoporosis? (Check all that apply) *

  31. Have you observed any difference in outcome after teriparatide treatment between males and females? *

  32. How do you monitor improvement with teriparatide in the management of severe osteoporosis? (Check all that apply) *

  33. According to you which one is better indicator to show favorable outcome with teriparatide in 3-6 months in osteoporosis management? *

  34. Teriparatide being an anabolic agent improves bone quality and prevents recurrence of fragility fractures in patients with osteoporotic fractures/features of severe osteoporosis *

  35. Maintenance treatment with antiresorptive agents (denosumab/bisphosphonates) can help to maintain improved bone mineral density achieved with teriparatide and prevent subsequent fractures *

  36. Assessment of bone formation marker P1NP can improve treatment compliance with teriparatide as patients themselves can see the improvement due to rise in P1NP levels *